Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,932 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PROGRESS Clear all
Recruiting No phase listed Observational

Evaluation of the Effects of a Rehabilitation Program in Individuals with Spine Pain

NCT04081896
View directory record Official record
Conditions
Neck Pain, Low Back Pain, Scoliosis, Thoracic Injuries
Interventions
Exercise
Other
Lead sponsor
SpineZone Medical Fitness, Inc
Other
Eligibility
18 Years to 89 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 30, 2026, 7:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigation of Increased Physical Activity During the Postpartum Period on Weight Loss, Body Composition, and Energy Expenditure

NCT06636305
View directory record Official record
Conditions
Weight Loss, Postpartum, Physical Activity
Interventions
physical activity intervention
Behavioral
Lead sponsor
Nicolas D. Knuth
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 30, 2026, 7:28 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Durvalumab, Tremelimumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
34
States / cities
Tucson, Arizona • Santa Rosa, California • New Haven, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 30, 2026, 7:28 PM EDT
Completed Phase 3 Interventional

An Interactive Internet Intervention for Adults With Insomnia

NCT01438697
View directory record Official record
Conditions
Insomnia, Sleep Initiation and Maintenance Disorders
Interventions
Internet Intervention, Patient Education Website
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 30, 2026, 7:28 PM EDT
Completed Not applicable Interventional Results available

Uniting Couples in the Treatment of Binge-Eating Disorder

NCT03784820
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
UNITE, CBT-E
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 30, 2026, 7:28 PM EDT
Terminated Phase 2 Interventional Results available

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

NCT01519427
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
Akt inhibitor MK2206, selumetinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Atlanta, Georgia • New Brunswick, New Jersey • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Oct 30, 2026, 7:28 PM EDT
Terminated Phase 2 Interventional Results available

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

NCT04488003
View directory record Official record
Conditions
Advanced Solid Tumor, BRAF Gene Mutation, BRAF Gene Alteration, MEK Mutation, MEK Alteration, MAP2K1 Gene Mutation, MAP2K1 Gene Alteration, MAP2K2 Gene Mutation, MAP2K2 Gene Alteration
Interventions
Ulixertinib, Physician's Choice
Drug
Lead sponsor
BioMed Valley Discoveries, Inc
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
22
States / cities
Phoenix, Arizona • Newport Beach, California • Newark, Delaware + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 30, 2026, 7:28 PM EDT
Terminated Phase 1 Interventional

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

NCT03218683
View directory record Official record
Conditions
Relapsed or Refractory Acute Myeloid Leukemia (AML)
Interventions
AZD5991, AZD5991 + Venetoclax
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
Orange, California • Aurora, Colorado • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 30, 2026, 7:28 PM EDT
Completed Not applicable Interventional Results available

Improving Providers' Decision-Making and Reducing Information Overload Using Information Visualization in EHRs

NCT05937646
View directory record Official record
Conditions
Electronic Health Records, Usability, Information Seeking Behavior, Critical Care
Interventions
AWARE, Electronic Health Record (EHR)
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 30, 2026, 7:28 PM EDT
Not listed Not applicable Interventional

Harm Reduction for Tobacco Smoking With Support of Tobacco-Replacing Electronic Nicotine Delivery Systems

NCT03962660
View directory record Official record
Conditions
Smoking, Tobacco
Interventions
HaRTS-TRENDS, Standard Care (SC)
Other
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 30, 2026, 7:28 PM EDT
Completed Early Phase 1 Interventional

Exercising Our ABC's (African- American Breast Cancer Survivors)

NCT01684579
View directory record Official record
Conditions
Breast Cancer
Interventions
Resistance Exercise, Aerobic Exercise, Behavioral Group Counseling
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Oct 30, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

NCT00038103
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Exemestane, Celecoxib + Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced Oct 30, 2026, 7:28 PM EDT
Completed Not applicable Interventional Results available

Pharmacist-led Group Medical Visits to Help With Diabetes Management

NCT00554671
View directory record Official record
Conditions
Diabetes Mellitus, Cardiovascular Diseases
Interventions
Algorithm driven medication titration, Monitoring, Group support, Self efficacy
Other · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
West Haven, Connecticut • Honolulu, Hawaii • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 30, 2026, 7:28 PM EDT
Recruiting Phase 1 Interventional

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

NCT07141706
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors
Interventions
DB-1317
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 30, 2026, 7:28 PM EDT
Completed Not applicable Interventional

Effects of Vestibular Rehabilitation in the Treatment of Dizziness and Balance Disturbances After Concussion

NCT06700252
View directory record Official record
Conditions
Concussion
Interventions
Vestibular Rehabilitation, Traditional Protocol
Other
Lead sponsor
Beth Marschner
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minot, North Dakota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 30, 2026, 7:28 PM EDT
Completed Not applicable Interventional

Development and Testing of Adolescent Twelve-Step Facilitation

NCT01449981
View directory record Official record
Conditions
Alcohol Abuse, Alcohol Dependence, Drug Abuse, Drug Dependence
Interventions
Integrated Twelve-Step Facilitation, Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2016 · Synced Oct 30, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

NCT00100932
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
E7389 28 Day Cycle, E7389 21 Day Cycle
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
13
States / cities
Gilroy, California • Ocala, Florida • Baltimore, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Oct 30, 2026, 7:28 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

CT Antigen TCR-Engineered T Cells for Myeloma

NCT01892293
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Treatment with NY-ESO-1c259-modified T cells
Drug
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Duarte, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 30, 2026, 7:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

NCT01941316
View directory record Official record
Conditions
Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
Interventions
Carfilzomib, Irinotecan
Drug
Lead sponsor
Cancer Research and Biostatistics Clinical Trials Consortium
Network
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Goodyear, Arizona • Lexington, Kentucky • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 30, 2026, 7:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intervention for Managing Physical Reactions to Overwhelming Emotions

NCT06299657
View directory record Official record
Conditions
Anxiety, Substance Use Disorders
Interventions
IMPROVE, PHET
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 30, 2026, 7:28 PM EDT
Active, not recruiting Early Phase 1 Interventional

Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)

NCT04634227
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma
Interventions
Ascorbate
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 30, 2026, 7:28 PM EDT
Terminated Not applicable Interventional

Registry-based HCV Care Cascade Navigation at Atlanta's Grady Memorial Hospital

NCT03441542
View directory record Official record
Conditions
Hepatitis C
Interventions
Data-assisted Case Navigation, Standard of Care
Behavioral
Lead sponsor
National Opinion Research Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 30, 2026, 7:28 PM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
39
States / cities
Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 7:28 PM EDT
Not listed Not applicable Interventional

Family-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study

NCT02058342
View directory record Official record
Conditions
Prader Willi Syndrome, Childhood Obesity
Interventions
Active Play at Home
Behavioral
Lead sponsor
California State University, Fullerton
Other
Eligibility
8 Years to 15 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Fullerton, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 30, 2026, 7:28 PM EDT